Crispr Therapeutics AG vs Levi Strauss & Co. — how do they compare? Crispr Therapeutics AG trades at $53.9 (market cap $5.23B), while Levi Strauss & Co. trades at $22.73 (market cap $8.75B). The key difference: Levi Strauss & Co. is the larger of the two by market cap, and Levi Strauss & Co. pays a 2.81% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | LEVI | |
|---|---|---|
Market Cap | $5.23B | $8.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $25.53 |
52-Week Low | $44.34 | $17.92 |
Enterprise Value | $3.65B | $10.07B |
Dividend Yield | — | 2.81% |
Trailing returns across standard periods
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →